On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden:: differences in treatment characteristics and outcome

被引:93
作者
Carlsson, KS
Höjgård, S
Glomstein, A
Lethagen, S
Schulman, S
Tengborn, L
Lindgren, A
Berntorp, E
Lindgren, B
机构
[1] Lund Univ, Ctr Hlth Econ, SE-22007 Lund, Sweden
[2] Malmo Univ Hosp, Dept Community Med, Lund, Sweden
[3] Inst Hemophilia, Oslo, Norway
[4] Lund Univ, Dept Coagulat Disorders, Malmo Univ Hosp, Malmo, Sweden
[5] Karolinska Hosp, Dept Med, Div Haematol, S-10401 Stockholm, Sweden
[6] Sahlgrens Univ Hosp, Dept Internal Med Cardiol & Vasc Surg, S-41345 Gothenburg, Sweden
[7] Lund Inst Technol, Ctr Math Sci, Lund, Sweden
关键词
days lost from work; factor-concentrate consumption; haemophilia-related surgery; longitudinal data; treatment characteristics; treatment strategy;
D O I
10.1046/j.1365-2516.2003.00817.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Using an 11-year panel of 156 Norwegian and Swedish patients with severe haemophilia, and including retrospective case-book data from birth, we compared the differences in the haemophilia-related resource use between on-demand and prophylactic treatment. Patients treated on-demand had more surgery (arthrodeses, prostheses implantations and synovectomies) and more days lost from work. Median annual factor-concentrate consumption among adults (18+) was 211 000 IU [interquartile range (IQR) 154 000-268 000] or 3 024 IU kg(-1) year(-1) for patients on prophylactic treatment and 55 000 IU (IQR 28 000-91 000) for on-demand patients (780 IU kg(-1) year(-1)). This was partly explained by the fact that the median dose per kg body weight was twice as great 28, (IQR 24-32) prophylaxis compared with 14 (IQR 12-16) for on-demand. Prescribed dose per kg body weight was found to be an important factor explaining the variation in total annual factor-concentrate consumption per patient for both types of treatment. Other variables included in the panel-data regression analysis were the number of weeks on secondary prophylaxis for on-demand patients and age, body weight and type of haemophilia for children (0-17 years) on prophylaxis. Differences were consistently substantial and will affect both costs and benefits of the two treatment strategies.
引用
收藏
页码:555 / 566
页数:12
相关论文
共 35 条
[1]   FREQUENCY OF INHIBITOR DEVELOPMENT IN HEMOPHILIACS TREATED WITH LOW-PURITY FACTOR-VIII [J].
ADDIEGO, J ;
KASPER, C ;
ABILDGAARD, C ;
HILGARTNER, M ;
LUSHER, J ;
GLADER, B ;
ALEDORT, L .
LANCET, 1993, 342 (8869) :462-464
[2]   A LONGITUDINAL-STUDY OF ORTHOPEDIC OUTCOMES FOR SEVERE FACTOR-VIII-DEFICIENT HEMOPHILIACS [J].
ALEDORT, LM ;
HASCHMEYER, RH ;
PETTERSSON, H ;
EIBL, H ;
GILBERT, M ;
HILGARTNER, M ;
KUNSHACK, M ;
LARRIEU, MJ ;
LEVINE, P .
JOURNAL OF INTERNAL MEDICINE, 1994, 236 (04) :391-399
[3]  
Baltagi B.H., 2008, Econometric Analysis of Panel Data, V3rd ed.
[4]  
BERNTORP E, 1987, EUR J HAEMATOL, V38, P256
[5]  
Berntorp E, 1995, B WORLD HEALTH ORGAN, V73, P691
[6]   METHODS OF HEMOPHILIA CARE DELIVERY - REGULAR PROPHYLAXIS VERSUS EPISODIC TREATMENT [J].
BERNTORP, E .
HAEMOPHILIA, 1995, 1 :3-7
[7]  
Bohn RL, 1998, THROMB HAEMOSTASIS, V79, P932
[8]  
BRAY GL, 1994, BLOOD, V83, P2428
[9]   Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A [J].
Carlsson, M ;
Berntorp, E ;
Bjorkman, S ;
Lethagen, S ;
Ljung, R .
HAEMOPHILIA, 1997, 3 (02) :96-101
[10]  
CARLSSON M, 1997, THESIS LUND U MALMO